share_log

Regeneron Pharmaceuticals | 8-K: Current report

Regeneron Pharmaceuticals | 8-K: Current report

再生元制药公司 | 8-K：重大事件
美股SEC公告 ·  2024/06/21 04:03

Moomoo AI 已提取核心信息

At Regeneron's 2024 Annual Meeting held on June 14, shareholders approved all proposed items on the agenda. Four Class III directors were elected to serve until 2027, including N. Anthony Coles, Kathryn Guarini, Arthur F. Ryan, and George L. Sing. Additionally, David P. Schenkein was elected as Class II director to serve until 2026.Shareholders ratified PricewaterhouseCoopers LLP as the independent registered public accounting firm for fiscal year 2024, with 111.35 million votes in favor. The advisory vote on executive compensation received strong support with 106.67 million votes in favor.Notably, the non-binding shareholder proposal requesting simple majority voting requirements was approved with 85.9 million votes in favor, representing significant shareholder support for this governance change.
At Regeneron's 2024 Annual Meeting held on June 14, shareholders approved all proposed items on the agenda. Four Class III directors were elected to serve until 2027, including N. Anthony Coles, Kathryn Guarini, Arthur F. Ryan, and George L. Sing. Additionally, David P. Schenkein was elected as Class II director to serve until 2026.Shareholders ratified PricewaterhouseCoopers LLP as the independent registered public accounting firm for fiscal year 2024, with 111.35 million votes in favor. The advisory vote on executive compensation received strong support with 106.67 million votes in favor.Notably, the non-binding shareholder proposal requesting simple majority voting requirements was approved with 85.9 million votes in favor, representing significant shareholder support for this governance change.
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    Enveric Biosciences
    ENVB
    -- 2.3000
    Renovaro
    RENB
    -- 1.190
    Moolec Science
    MLEC
    -- 0.850
    Salarius Pharmaceuticals
    SLRX
    -- 1.4500
    Channel Therapeutics
    CHRO
    -- 2.230
    解锁完整榜单
    重估中国资产
    继中国开创性的DeepSeek技术推出之后， 华尔街大行重估对中国市场的投资前景。
    热门讨论
    科技巨头财报季如火如荼，英伟达压轴会表现如何？
    星期四， $亚马逊 (AMZN.US)$ 股价在公司报告第四季度调整后每股收益为1.86美元，预估为每股1.50美元，营业收入为1877.9亿，预估为1873.2亿后下跌。该公司预测第一季度的营业收入数字低于华尔街的预期，预测本季度最多为1550亿，而分析师希望为1580亿。 星 展开
    亚马逊盈利预告：猜测开盘价，获取奖励！